Search results
Results from the WOW.Com Content Network
docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide: breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. [11] It is administered by intravenous injection. [11] There is also an albumin-bound formulation. [11]
Sometimes hair has a tendency to curl after regrowth, resulting in "chemo curls." Severe hair loss occurs most often with drugs such as doxorubicin, daunorubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide and etoposide. Permanent thinning or hair loss can result from some standard chemotherapy regimens. [101]
The structure of paclitaxel, a widely used mitotic inhibitor.. A mitotic inhibitor, microtubule inhibitor, or tubulin inhibitor, is a drug that inhibits mitosis, or cell division, and is used in treating cancer, gout, and nail fungus.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 30 ] [ 27 ] [ 31 ] [ 32 ] It is specifically used for cancer that is HER2 receptor positive . [ 30 ]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
a phase III trial for HER2+ gastric cancer compares T-DM1 to physician's choice of taxane (docetaxel or paclitaxel). [35] On 22 October 2015, Roche and co-developer ImmunoGen disclosed that trastuzumab emtansine had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2 -positive ...